Anxiety levels before biologic initiation and changes with treatment in patients with psoriatic arthritis: HUR-BIO biologic registry results

Ayan, G.; Farisoğullari, B.; Bılgın, Emre; Bolek, E. C.; KübraYardımcı, Gozde; Duran, E.; Özsoy, Z.; Uzun, Gülay; Kılıç, Levent; Akdoğan, Ali; Karadağ, Ömer; Bilgen, Şule Apraş; Kiraz, Sedat; Ertenli, Ali İhsan; Kalyoncu, Umut

doi:10.1007/s10067-021-06012-y

Cited by 1 publication

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is reasonable to assume that this improvement in QoL is stronger the more effective the treatment is. Moreover, an improvement in anxiety symptoms with psoriasis therapy has been reported [ 100 ] in association with better clinical outcomes [ 19 ]. Biologic use is also associated with a lower risk of depressive symptoms when compared with placebo [ 101 ] or conventional therapy [ 20 ].…”

Section: Targeted Pharmacotherapies May Reduce the Burden Of The Cumu...mentioning

confidence: 99%

Could Targeted Pharmacotherapies Exert a “Disease Modification Effect” in Patients with Chronic Plaque Psoriasis?

Bellinato

Chiricozzi

Piaserico

et al. 2022

IJMS

View full text Add to dashboard Cite

Chronic plaque psoriasis is an immune-mediated skin disease with a chronic relapsing course, affecting up to ~2–3% of the general adult population worldwide. The interleukin (IL)-23/Th17 axis plays a key role in the pathogenesis of this skin disease and may represent a critical target for new targeted pharmacotherapies. Cutaneous lesions tend to recur in the same body areas, likely because of the reactivation of tissue-resident memory T cells. The spillover of different pro-inflammatory cytokines into systemic circulation can promote the onset of different comorbidities, including psoriatic arthritis. New targeted pharmacotherapies may lead to almost complete skin clearance and significant improvements in the patient’s quality of life. Accumulating evidence supports the notion that early intervention with targeted pharmacotherapies could beneficially affect the clinical course of psoriatic disease at three different levels: (1) influencing the immune cells infiltrating the skin and gene expression, (2) the prevention of psoriasis-related comorbidities, especially psoriatic arthritis, and (3) the improvement of the patient’s quality of life and reduction of cumulative life course impairment. The main aim of this narrative review is to summarize the effects that new targeted pharmacotherapies for psoriasis may have on the immune scar, both at the molecular and cellular level, on psoriatic arthritis and on the patient’s quality of life.

show abstract

Section: Targeted Pharmacotherapies May Reduce the Burden Of The Cumu...mentioning

confidence: 99%

Could Targeted Pharmacotherapies Exert a “Disease Modification Effect” in Patients with Chronic Plaque Psoriasis?

Bellinato

Chiricozzi

Piaserico

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

Anxiety levels before biologic initiation and changes with treatment in patients with psoriatic arthritis: HUR-BIO biologic registry results

Cited by 1 publication

References 20 publications

Could Targeted Pharmacotherapies Exert a “Disease Modification Effect” in Patients with Chronic Plaque Psoriasis?

Could Targeted Pharmacotherapies Exert a “Disease Modification Effect” in Patients with Chronic Plaque Psoriasis?

Contact Info

Product

Resources

About